Učitavanje...
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneop...
Spremljeno u:
| Izdano u: | J Clin Biochem Nutr |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
the Society for Free Radical Research Japan
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4865599/ https://ncbi.nlm.nih.gov/pubmed/27257345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3164/jcbn.15-127 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|